[Updates on rickets and osteomalacia: anti-FGF23 antibody, a new therapeutic approach for hypophosphatemic rickets/osteomalacia].

Abstract

In the last decade, Fibroblast growth factor (FGF) 23 has been shown to be a causative factor of hypophosphatemic rickets/osteomalacia, and considered as potential therapeutic target for this disease. Now the most attention is paid to FGF23 blockades as a new category of therapy that may replace the current supplementation of phosphate and active vitamin D. In this chapter, pharmacological actions of the FGF23-neutralizing antibodies in murine hypophosphatemic rickets/osteomalacia model are reviewed. In addition, other types of FGF23 blockades are also briefly discussed.

• Authors: Takashi Shimada
• Journal: Clinical calcium (Clin Calcium) Vol. 23 Issue 10 Pg. 1469-75 (Oct 2013) ISSN: 0917-5857 [Print] Japan
• PMID: 24076645 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Neutralizing
• FGF23 protein, human
• Phosphates
• Fibroblast Growth Factors
• Fibroblast Growth Factor-23
• Glucuronidase
• Klotho Proteins

Topics

• Animals
• Antibodies, Neutralizing (blood, pharmacology)
• Disease Models, Animal
• Fibroblast Growth Factor-23
• Fibroblast Growth Factors (immunology)
• Glucuronidase (metabolism)
• Humans
• Klotho Proteins
• Phosphates (blood)
• Rickets, Hypophosphatemic (immunology, metabolism)